


What is claim d is:

1. A composition for prevention, amelioration or control of external parasites on animals and humans comprising a pharmaceutically acceptable carrier and an ectoparasitically effective amount of a compound of formula I



(I)

or a pharmaceutically acceptable salt thereof wherein

R is halogen, OR₇, SO_mR₈, NO₂, CN, C₁-C₆haloalkyl or an optionally substituted C₁-C₆alkyl group;

n is 0 or an integer of 1, 2 or 3;

m is 0 or an integer of 1 or 2;

R₁ is H, halogen, NO₂, NR₉R₁₀, NR₁₁COR₁₂, NCHNR₉R₁₀ or NCHOR₁₃;

R₂, R₃, R₄, R₅ and R₆ are each independently H, halogen or a C₁-C₄alkyl, aryl or heteroaryl group each optionally substituted;

R₇ is H or a C₁-C₆alkyl, C₂-C₆alkenyl, C₂-C₆alkynyl, aryl or heteroaryl group each optionally substituted;

R₈ is a C₁-C₆alkyl, C₂-C₆alkenyl, C₂-C₆alkynyl, aryl or heteroaryl group, each optionally substituted;

R₉ and R₁₀ are each independently H, C₁-C₄haloalkyl or a C₁-C₆alkyl, C₂-C₆alkenyl, C₂-C₆alkynyl, aryl or heteroaryl group each optionally substituted or R₉ and R₁₀ may be taken together with the atom to which they are attached to form a 5- to 7-membered ring optionally containing 1 or 2 additional heteroatoms selected from O, N or S;

R₁₁ is H, COR₁₂ or an optionally substituted C₁-C₄alkyl group;

R₁₂ is a C₁-C₆alkyl, C₂-C₆alkenyl, C₂-C₆alkynyl, aryl or heteroaryl group each optionally substituted; and

R₁₃ is H or a C₁-C₆alkyl, aryl or heteroaryl group each optionally substituted;

or a stereoisomer or tautomer thereof.

2. The composition according to claim 1 wherein formula I has the proviso that R₃, R₄, R₅ and R₆ are not all -H, unless R₁ is halogen.
3. The composition according to claim 2 wherein R is halogen or haloalkyl.
4. The composition according to claim 2 wherein R₁ is H, halogen or NR₉R₁₀.
5. The composition according to claim 1 wherein R₅ and R₆ are H.
6. The composition according to claim 3 wherein R₂ is H, halogen, methyl or an optionally substituted phenyl group.
7. The composition according to claim 6 wherein R₁ is H or Cl.
8. The composition according to claim 7 wherein R is halogen or CF₃ and n is 3.
9. The composition according to claim 8 wherein R₂ is Cl or methyl and R₃ and R₄ are each independently H, Cl or Br.
10. The composition according to claim 2 wherein said compound is selected from the group consisting of:
5-chloro-3-(2,2-dichloro-1-methylcyclopropyl)-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazole-4-carbonitrile;
3-(2,2-dichloro-1-methylcyclopropyl)-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazole-4-carbonitrile;
3-(2,2-dichloro-1-methylcyclopropyl)-1-(2,4,6-trichlorophenyl)-1H-pyrazole-4-carbonitrile;
3-(2,2-dichloro-1,3-dimethylcyclopropyl)-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazole-4-carbonitrile;
3-(2,2-dibromo-1-methylcyclopropyl)-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazole-4-carbonitrile;


- 3-(2,2-dibromo-1-methylcyclopropyl)-1-(2,4,6-trichlorophenyl)-1H-pyrazole-4-carbonitrile;
- 3-(2,2-dichloro-1-methylcyclopropyl)-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazole-4-carbonitrile;
- 5 5-chloro-3-(2,2-dibromo-1-methylcyclopropyl)-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazole-4-carbonitrile;
- 5-amino-3-(2,2-dibromo-1-methylcyclopropyl)-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazole-4-carbonitrile;
- 5-bromo-3-(2,2-dibromo-1-methylcyclopropyl)-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazole-4-carbonitrile;
- 10 5-amino-3-(2,2-dichloro-1-methylcyclopropyl)-1-(2,4,6-trichlorophenyl)-1H-pyrazole-4-carbonitrile;
- 5-chloro-3-cyclopropyl-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazole-4-carbonitrile;
- 15 5-chloro-3-(2,2-dichloro-1-methylcyclopropyl)-1-(2,4,6-trichlorophenyl)-1H-pyrazole-4-carbonitrile;
- 5-bromo-3-(2,2-dichloro-1-methylcyclopropyl)-1-(2,4,6-trichlorophenyl)-1H-pyrazole-4-carbonitrile;
- 5-bromo-3-(2,2-dichloro-1-methylcyclopropyl)-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazole-4-carbonitrile;
- 20 3-(2,2-dichloro-1-methylcyclopropyl)-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-5-nitro-1H-pyrazole-4-carbonitrile;
- 3-(2,2-dichloro-1-methylcyclopropyl)-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-5-iodo-1H-pyrazole-4-carbonitrile;
- 25 3-(2,2-dichloro-1-methylcyclopropyl)-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-5-(dimethylamino)-1H-pyrazole-4-carbonitrile;
- 3-(2,2-dichloro-1-methylcyclopyrazol)-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-5-(diethylamino)-1H-pyrazole-4-carbonitrile;
- 5-[(cyclopropanecarbonyl)amino]-3-(2,2-dichloro-1-methylcyclopropyl)-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazole-4-carbonitrile;
- 30 N-{4-cyano-5-(2,2-dichloro-1-methyl-cyclopropyl)-2-[2,6-dichloro-4-(trifluoromethyl)phenyl]-2H-pyrazol-3-yl}-formimidic acid methyl ester;

N-{4-cyano-5-(2,2-dichloro-1-methyl-cyclopropyl)-2-[2,6-dichloro-4-(trifluoromethyl)-phenyl]-2-H-pyrazol-3-yl}-formimidic acid propyl ester;

N-{4-cyano-5-(2,2-dichloro-1-methyl-cyclopropyl)-2-[2,6-dichloro-4-(trifluoromethyl)-phenyl]-2H-pyrazol-3-yl}-formimidic acid ethyl ester;

- 5 the stereoisomers thereof; and the tautomers thereof; or a pharmaceutically acceptable salt thereof.

11. A method for the prevention, amelioration or control of ectoparasitic infection or infestation in a homeothermic animal which comprises providing to a homeothermic animal in need thereof a prophylactically, therapeutically or pharmaceutically effective amount of a compound of formula I



(I)

or a pharmaceutically acceptable salt thereof wherein

- 15 R is halogen, OR₇, SO_mR₈, NO₂, CN, C₁-C₆haloalkyl or an optionally substituted C₁-C₆alkyl group;
 n is 0 or an integer of 1, 2 or 3;
 m is 0 or an integer of 1 or 2;
 R₁ is H, halogen, NO₂, NR₉R₁₀, NR₁₁COR₁₂, NCHNR₉R₁₀ or NCHOR₁₃;
 R₂, R₃, R₄, R₅ and R₆ are each independently H, halogen or a C₁-C₄alkyl, aryl or heteroaryl group each optionally substituted;
 20 R₇ is H or a C₁-C₆alkyl, C₂-C₆alkenyl, C₂-C₆alkynyl, aryl or heteroaryl group each optionally substituted;
 R₈ is a C₁-C₆alkyl, C₂-C₆alkenyl, C₂-C₆alkynyl, aryl or heteroaryl group, each optionally substituted;
 25 R₉ and R₁₀ are each independently H, C₁-C₄haloalkyl or a C₁-C₆alkyl, C₂-C₆alkenyl, C₂-C₆alkynyl, aryl or heteroaryl group each optionally substituted or R₉ and R₁₀ may be taken together with the atom to

which they are attached to form a 5- to 7-membered ring optionally containing 1 or 2 additional heteroatoms selected from O, N or S;

R₁₁ is H, COR₁₂ or an optionally substituted C₁-C₄alkyl group;

R₁₂ is a C₁-C₆alkyl, C₂-C₆alkenyl, C₂-C₆alkynyl, aryl or heteroaryl group each optionally substituted; and

R₁₃ is H or a C₁-C₆alkyl, aryl or heteroaryl group each optionally substituted; or a stereoisomer or tautomer thereof.

12. The method according to claim 11 wherein the formula I has the proviso that R₃, R₄, R₅ and R₆ are not all -H, unless R₁ is halogen.

13. The method according to claim 12 wherein R is halogen or haloalkyl and n is 3.

14. The method according to claim 13 wherein R₅ and R₆ are H.

15. The method according to claim 14 wherein R₂ is H, halogen, methyl or an optionally substituted phenyl group.

16. The method according to claim 12 wherein the ectoparasite is selected from the group consisting of Diptera; Muscidae; Acarina; and Siphonaptera.

17. The method according to claim 16 wherein the ectoparasite is selected from the group consisting of fleas; ticks; lice; blow flies; face flies and horn flies.

18. The method according to claim 16 wherein the homeothermic animal is selected from the group consisting of cattle; sheep; horse; goat; pig; camel; water buffalo; donkey; rabbit; fallow deer; reindeer; mink; chinchilla; raccoon; chicken; geese; turkey; duck; dog and cat.

19. The method according to claim 17 wherein the homeothermic animal is selected from the group consisting of cattle, sheep, horse, dog, and cat.

20. A veterinary pour-on composition which comprises: a spreading oil; an aliphatic or aromatic hydrocarbon, mono or polyhydric alcohol, a C₁-C₁₀ alkyl

ketone, or a mixture thereof; and an ectoparasitically effective amount of a compound of formula I according to claim 1.

21. The composition according to claim 20 wherein formula I has the
5 proviso that R₃, R₄, R₅ and R₆ are not all -H, unless R₁ is halogen.

22. The composition according to claim 21 wherein R is halogen or haloalkyl and n is 3.

23. The composition according to claim 22 wherein said compound is selected from the group consisting of:

10 5-chloro-3-(2,2-dichloro-1-methylcyclopropyl)-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazole-4-carbonitrile;
3-(2,2-dichloro-1-methylcyclopropyl)-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazole-4-carbonitrile;
3-(2,2-dichloro-1-methylcyclopropyl)-1-(2,4,6-trichlorophenyl)-1H-pyrazole-4-
15 carbonitrile;
3-(2,2-dichloro-1,3-dimethylcyclopropyl)-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazole-4-carbonitrile;
3-(2,2-dibromo-1-methylcyclopropyl)-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazole-4-carbonitrile;
20 3-(2,2-dibromo-1-methylcyclopropyl)-1-(2,4,6-trichlorophenyl)-1H-pyrazole-4-carbonitrile;
3-(2,2-dichloro-1-methylcyclopropyl)-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazole-4-carbonitrile;
5-chloro-3-(2,2-dibromo-1-methylcyclopropyl)-1-[2,6-dichloro-4-
25 (trifluoromethyl)phenyl]-1H-pyrazole-4-carbonitrile;
5-amino-3-(2,2-dibromo-1-methylcyclopropyl)-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazole-4-carbonitrile;
5-bromo-3-(2,2-dibromo-1-methylcyclopropyl)-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazole-4-carbonitrile;
30 5-amino-3-(2,2-dichloro-1-methylcyclopropyl)-1-(2,4,6-trichlorophenyl)-1H-pyrazole-4-carbonitrile;

- 5-chloro-3-cyclopropyl-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazole-4-carbonitrile;
- 5-chloro-3-(2,2-dichloro-1-methylcyclopropyl)-1-(2,4,6-trichlorophenyl)-1H-pyrazole-4-carbonitrile;
- 5 5-bromo-3-(2,2-dichloro-1-methylcyclopropyl)-1-(2,4,6-trichlorophenyl)-1H-pyrazole-4-carbonitrile;
- 5-bromo-3-(2,2-dichloro-1-methylcyclopropyl)-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazole-4-carbonitrile;
- 3-(2,2-dichloro-1-methylcyclopropyl)-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-5-nitro-1H-pyrazole-4-carbonitrile;
- 10 3-(2,2-dichloro-1-methylcyclopropyl)-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-5-iodo-1H-pyrazole-4-carbonitrile;
- 3-(2,2-dichloro-1-methylcyclopropyl)-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-5-(dimethylamino)-1H-pyrazole-4-carbonitrile;
- 15 3-(2,2-dichloro-1-methylcyclopyrazol)-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-5-(diethylamino)-1H-pyrazole-4-carbonitrile;
- 5-[(cyclopropanecarbonyl)amino]-3-(2,2-dichloro-1-methylcyclopropyl)-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazole-4-carbonitrile;
- N-{4-cyano-5-(2,2-dichloro-1-methyl-cyclopropyl)-2-[2,6-dichloro-4-(trifluoromethyl)-phenyl]-2H-pyrazol-3-yl}-formimidic acid methyl ester;
- 20 N-{4-cyano-5-(2,2-dichloro-1-methyl-cyclopropyl)-2-[2,6-dichloro-4-(trifluoromethyl)-phenyl]-2-H-pyrazol-3-yl}-formimidic acid propyl ester;
- N-{4-cyano-5-(2,2-dichloro-1-methyl-cyclopropyl)-2-[2,6-dichloro-4-(trifluoromethyl)-phenyl]-2-H-pyrazol-3-yl}-formimidic acid ethyl ester;
- 25 the stereoisomers thereof; and the tautomers thereof.

24. A veterinary pour-on composition which comprises: approximately 40-50% by weight xylene; approximately 20-30% by weight cyclohexanone; approximately 5-15% vegetable or mineral oil or a combination thereof; and approximately 10-25% of a compound selected from the group consisting of:
- 30 5-chloro-3-(2,2-dichloro-1-methylcyclopropyl)-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazole-4-carbonitrile;
- 3-(2,2-dichloro-1-methylcyclopropyl)-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazole-4-carbonitrile;

- 3-(2,2-dichloro-1-methylcyclopropyl)-1-(2,4,6-trichlorophenyl)-1H-pyrazole-4-carbonitrile;
- 3-(2,2-dichloro-1,3-dimethylcyclopropyl)-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazole-4-carbonitrile;
- 5 3-(2,2-dibromo-1-methylcyclopropyl)-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazole-4-carbonitrile;
- 3-(2,2-dibromo-1-methylcyclopropyl)-1-(2,4,6-trichlorophenyl)-1H-pyrazole-4-carbonitrile;
- 10 3-(2,2-dichloro-1-methylcyclopropyl)-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazole-4-carbonitrile;
- 5-chloro-3-(2,2-dibromo-1-methylcyclopropyl)-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazole-4-carbonitrile;
- 5-amino-3-(2,2-dibromo-1-methylcyclopropyl)-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazole-4-carbonitrile;
- 15 5-bromo-3-(2,2-dibromo-1-methylcyclopropyl)-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazole-4-carbonitrile;
- 5-amino-3-(2,2-dichloro-1-methylcyclopropyl)-1-(2,4,6-trichlorophenyl)-1H-pyrazole-4-carbonitrile;
- 5-chloro-3-cyclopropyl-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazole-4-carbonitrile;
- 20 5-chloro-3-(2,2-dichloro-1-methylcyclopropyl)-1-(2,4,6-trichlorophenyl)-1H-pyrazole-4-carbonitrile;
- 5-bromo-3-(2,2-dichloro-1-methylcyclopropyl)-1-(2,4,6-trichlorophenyl)-1H-pyrazole-4-carbonitrile;
- 25 5-bromo-3-(2,2-dichloro-1-methylcyclopropyl)-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazole-4-carbonitrile;
- 3-(2,2-dichloro-1-methylcyclopropyl)-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-5-nitro-1H-pyrazole-4-carbonitrile;
- 3-(2,2-dichloro-1-methylcyclopropyl)-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-5-iodo-1H-pyrazole-4-carbonitrile;
- 30 3-(2,2-dichloro-1-methylcyclopropyl)-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-5-(dimethylamino)-1H-pyrazole-4-carbonitrile;

- 3-(2,2-dichloro-1-methylcyclopyrazol)-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-5-(diethylamino)-1H-pyrazole-4-carbonitrile;
 5-[(cyclopropanecarbonyl)amino]-3-(2,2-dichloro-1-methylcyclopropyl)-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazole-4-carbonitrile;
- 5 N-{4-cyano-5-(2,2-dichloro-1-methyl-cyclopropyl)-2-[2,6-dichloro-4-(trifluoromethyl)-phenyl]-2H-pyrazol-3-yl}-formimidic acid methyl ester;
 N-{4-cyano-5-(2,2-dichloro-1-methyl-cyclopropyl)-2-[2,6-dichloro-4-(trifluoromethyl)-phenyl]-2-H-pyrazol-3-yl}-formimidic acid propyl ester;
 N-{4-cyano-5-(2,2-dichloro-1-methyl-cyclopropyl)-2-[2,6-dichloro-4-(trifluoromethyl)-phenyl]-2-H-pyrazol-3-yl}-formimidic acid ethyl ester;
- 10 the stereoisomers thereof; and the tautomers thereof.

25. The composition according to claim 24 wherein an effective dosage of said compound is within the range of about 0.1 mg/kg to 100 mg/kg of animal body weight.

15


26. A veterinary composition which comprises a pharmaceutically acceptable carrier and about 0.1 ppm to 5000 ppm of a compound selected from the group consisting of:
- 20 5-chloro-3-(2,2-dichloro-1-methylcyclopropyl)-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazole-4-carbonitrile;
 3-(2,2-dichloro-1-methylcyclopropyl)-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazole-4-carbonitrile;
 3-(2,2-dichloro-1-methylcyclopropyl)-1-(2,4,6-trichlorophenyl)-1H-pyrazole-4-carbonitrile;
- 25 3-(2,2-dichloro-1,3-dimethylcyclopropyl)-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazole-4-carbonitrile;
 3-(2,2-dibromo-1-methylcyclopropyl)-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazole-4-carbonitrile;
- 30 3-(2,2-dibromo-1-methylcyclopropyl)-1-(2,4,6-trichlorophenyl)-1H-pyrazole-4-carbonitrile;
 3-(2,2-dichloro-1-methylcyclopropyl)-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazole-4-carbonitrile;

- 5-chloro-3-(2,2-dibromo-1-methylcyclopropyl)-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazole-4-carbonitrile;
 5-amino-3-(2,2-dibromo-1-methylcyclopropyl)-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazole-4-carbonitrile;
- 5 5-bromo-3-(2,2-dibromo-1-methylcyclopropyl)-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazole-4-carbonitrile;
 5-amino-3-(2,2-dichloro-1-methylcyclopropyl)-1-(2,4,6-trichlorophenyl)-1H-pyrazole-4-carbonitrile;
 5-chloro-3-cyclopropyl-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazole-4-
- 10 carbonitrile;
 5-chloro-3-(2,2-dichloro-1-methylcyclopropyl)-1-(2,4,6-trichlorophenyl)-1H-pyrazole-4-carbonitrile;
 5-bromo-3-(2,2-dichloro-1-methylcyclopropyl)-1-(2,4,6-trichlorophenyl)-1H-pyrazole-4-carbonitrile;
- 15 5-bromo-3-(2,2-dichloro-1-methylcyclopropyl)-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazole-4-carbonitrile;
 3-(2,2-dichloro-1-methylcyclopropyl)-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-5-nitro-1H-pyrazole-4-carbonitrile;
 3-(2,2-dichloro-1-methylcyclopropyl)-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-5-iodo-
- 20 1H-pyrazole-4-carbonitrile;
 3-(2,2-dichloro-1-methylcyclopropyl)-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-5-(dimethylamino)-1H-pyrazole-4-carbonitrile;
 3-(2,2-dichloro-1-methylcyclopyrazol)-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-5-(diethylamino)-1H-pyrazole-4-carbonitrile;
- 25 5-[(cyclopropanecarbonyl)amino]-3-(2,2-dichloro-1-methylcyclopropyl)-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazole-4-carbonitrile;
 N-{4-cyano-5-(2,2-dichloro-1-methyl-cyclopropyl)-2-[2,6-dichloro-4-(trifluoromethyl)phenyl]-2H-pyrazol-3-yl}-formimidic acid methyl ester;
 N-{4-cyano-5-(2,2-dichloro-1-methyl-cyclopropyl)-2-[2,6-dichloro-4-(trifluoromethyl)phenyl]-2-H-pyrazol-3-yl}-formimidic acid propyl ester;
- 30 N-{4-cyano-5-(2,2-dichloro-1-methyl-cyclopropyl)-2-[2,6-dichloro-4-(trifluoromethyl)phenyl]-2-H-pyrazol-3-yl}-formimidic acid ethyl ester;
 the stereoisomers thereof; and the tautomers thereof.

27. The composition according to claim 26 which comprises about 0.5 ppm to 1000 ppm of said compound.

5 28. The composition according to claim 27 which comprises about 0.2 ppm to 20 ppm of said compound.

29. A compound of formula I



(I)

10 or a pharmaceutically acceptable salt thereof wherein

R is halogen, OR₇, SO_mR₈, NO₂, CN, C₁-C₆haloalkyl or an optionally substituted C₁-C₆alkyl group;

n is 0 or an integer of 1, 2 or 3;

m is 0 or an integer of 1 or 2;

15 R₁ is H, halogen, NO₂, NR₉R₁₀, NR₁₁COR₁₂, NCHNR₉R₁₀ or NCHOR₁₃;

R₂, R₃, R₄, R₅ and R₆ are each independently H, halogen or a C₁-C₄alkyl, aryl or heteroaryl group each optionally substituted;

R₇ is H or a C₁-C₆alkyl, C₂-C₆alkenyl, C₂-C₆alkynyl, aryl or heteroaryl group each optionally substituted;

20 R₈ is a C₁-C₆alkyl, C₂-C₆alkenyl, C₂-C₆alkynyl, aryl or heteroaryl group, each optionally substituted;

R₉ and R₁₀ are each independently H, C₁-C₄haloalkyl or a C₁-C₆alkyl, C₂-C₆alkenyl, C₂-C₆alkynyl, aryl or heteroaryl group each optionally substituted or R₉ and R₁₀ may be taken together with the atom to

25 which they are attached to form a 5- to 7-membered ring optionally containing 1 or 2 additional heteroatoms selected from O, N or S;

R₁₁ is H, COR₁₂ or an optionally substituted C₁-C₄alkyl group;

R_{12} is a C_1 - C_6 alkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, aryl or heteroaryl group each optionally substituted; and

R_{13} is H or a C_1 - C_6 alkyl, aryl or heteroaryl group each optionally substituted; or a stereoisomer or tautomer thereof.

5

30. The compound of claim 29 wherein formula I has the proviso that R_3 , R_4 , R_5 and R_6 are not all -H, unless R_1 is halogen.